How many high production chemicals are rodent carcinogens? Why should we care? What do we need to do about it?

被引:5
|
作者
Johnson, FM [1 ]
机构
[1] NIEHS, Res Triangle Pk, NC 27709 USA
关键词
cancer; carcinogens; National Toxicology Program; Environmental Protection Agency; high production chemicals; rodent bioassay; NTP; EPA; HPV;
D O I
10.1016/S1383-5742(02)00091-1
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
High production volume (HPV) chemicals are produced in or imported to the US in amounts greater than I million pounds per chemical per year. The EPA has identified thousands of HPVs. Due to their abundance, such chemicals bring a substantial risk for human exposure, and as a result some level of adverse consequences to health are to be expected. In order to examine the potential for cancer risk associated with HPVs, this paper examines HPVs that have been tested in the National Toxicology Program's rodent cancer bioassay. The chemicals tested in the bioassay represent a small sample of the universe of environmental chemicals to which people are exposed. Unexpectedly, 60% of the 128 HPVs evaluated in the bioassay proved to be rodent carcinogens. This value compares to a predicted prevalence of only 16.5% carcinogens in a previous study. The previous study concluded that HPVs were less likely to be toxic by a variety of other test criteria as well. However, the approach involved identifying putative carcinogens using quantitative chemical structure-activity relationships QSAR) in contrast to the direct tabulation of bioassay test results performed here. Detailed examination of bioassay results reveals that test outcomes depend heavily on route of administration as well as on dose level, sex, strain, and species used. Since most of these factors have little or no apparent relationship to chemical structure, results of this study suggest that QSAR, as well as virtually all other alternative methods, may not generally provide accurate predictions of carcinogenic potential. As we wait for efficient and effective methods for predicting carcinogens to be developed, people continue to be exposed to environmental carcinogens. Progress on regulating environmental carcinogens as well as on developing more effective test methods has been minimal since "war on cancer" began approximately 30 years ago. The present study questions whether the current strategy for dealing with environmental carcinogens will ever be successful. Close examination of rodent cancer test results seems to suggest that almost all chemicals may have carcinogenic potential in some genotypes under some exposure circumstances. If this hypothesis is correct, it would explain the general lack of progress in developing methods to differentiate carcinogens from noncarcinogens. A completely new strategy for dealing with cancer caused by exposures to environmental chemicals seems to be needed. Published by Elsevier Science B.V.
引用
收藏
页码:201 / 215
页数:15
相关论文
共 50 条
  • [41] Why do we keep reporting high-grade prostatic intraepithelial neoplasia (HGPIN)?
    Leite, Katia R. M.
    INTERNATIONAL BRAZ J UROL, 2016, 42 (02): : 180 - 182
  • [42] Palliative care and quality of life needs and outcomes for Maori with cancer: what do we know?
    Jones, Rhiannon Mihi
    Signal, Virginia
    Smith, Moira
    Stairmand, Jeannine
    Davies, Cheryl
    Gurney, Jason
    ALTERNATIVE-AN INTERNATIONAL JOURNAL OF INDIGENOUS PEOPLES, 2023, 19 (02) : 219 - 228
  • [43] The knowledge, attitude and behavior on the palliative care among neonatal nurses: what can we do
    Yan, Yilan
    Hu, Jiahui
    Hu, Fei
    Wu, Longyan
    BMC PALLIATIVE CARE, 2024, 23 (01):
  • [44] Resecting or Burning: What Should We Do With the Remaining Barrett's Epithelium After Successful ER of Neoplasia ?
    Pech, Oliver
    Ell, Christian
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 (11): : 2693 - 2694
  • [45] What do we need to make genetic biomarker-guided treatment for renal cell carcinoma a reality?
    Diekstra, Meta H.
    Liu, Xiaoyan
    Swen, Jesse J.
    Guchelaar, Henk-Jan
    PHARMACOGENOMICS, 2017, 18 (01) : 1 - 4
  • [46] Immune checkpoint inhibitors for advanced or metastatic basal cell carcinoma: how much evidence do we need?
    Moujaess, Elissar
    Merhy, Reine
    Kattan, Joseph
    Sarkis, Anne-Sophie
    Tomb, Roland
    IMMUNOTHERAPY, 2021, 13 (15) : 1293 - 1304
  • [47] Spouses of Patients With Cancer Have an Increased Risk of Cardiovascular Disease What Do We Know About This Link?
    Schneiderman, Neil
    Kim, Youngmee
    Shaffer, Kelly M.
    CIRCULATION, 2012, 125 (14) : 1721 - 1722
  • [48] Overview of premedication prescription and intake in an oncology day hospital: What do we need to change to improve patient management?
    Goubil, Annabel
    Lallier, Laurine
    Peyrilles, Elodie
    Coupez, Dahna
    Gouill, Christele Le
    Fronteau, Clementine
    Cormier, Nicolas
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024, 30 (01) : 88 - 99
  • [49] What do we know about dynamic glucose-enhanced (DGE) MRI and how close is it to the clinics? Horizon 2020 GLINT consortium report
    Mina Kim
    Afroditi Eleftheriou
    Luca Ravotto
    Bruno Weber
    Michal Rivlin
    Gil Navon
    Martina Capozza
    Annasofia Anemone
    Dario Livio Longo
    Silvio Aime
    Moritz Zaiss
    Kai Herz
    Anagha Deshmane
    Tobias Lindig
    Benjamin Bender
    Xavier Golay
    Magnetic Resonance Materials in Physics, Biology and Medicine, 2022, 35 : 87 - 104
  • [50] What do we know about dynamic glucose-enhanced (DGE) MRI and how close is it to the clinics? Horizon 2020 GLINT consortium report
    Kim, Mina
    Eleftheriou, Afroditi
    Ravotto, Luca
    Weber, Bruno
    Rivlin, Michal
    Navon, Gil
    Capozza, Martina
    Anemone, Annasofia
    Longo, Dario Livio
    Aime, Silvio
    Zaiss, Moritz
    Herz, Kai
    Deshmane, Anagha
    Lindig, Tobias
    Bender, Benjamin
    Golay, Xavier
    MAGNETIC RESONANCE MATERIALS IN PHYSICS BIOLOGY AND MEDICINE, 2022, 35 (01) : 87 - 104